Skip to main content

Table 3 Relationship between nuclear ADA3 and nuclear c-MYC co-expression combinatorial phenotypic groups with molecular biomarker status within the whole unselected invasive breast cancer series (n = 588 cases)

From: ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC

  ADA3low C MYClow
N (%)
ADA3high C MYClow
N (%)
ADA3low C MYChigh
N (%)
ADA3high C MYChigh
N (%)
Significance
X 2 P
ER Status Negative 59 (39.6) 12 (8.1) 56 (37.6) 22 (14.8) 25.800 <0.001
Positive 113 (26.0) 56 (12.9) 121 (27.9) 144 (33.2)
PR Status Negative 78 (36.0) 25 (10.3) 74 (30.6) 56 (23.1) 12.803 0.005
Positive 79 (23.7) 43 (12.9) 102 (30.5) 110 (32.9)
HER2 Status* Negative 6 (54.5) 2 (18.2) 1 (9.1) 2 (18.2) 21.743 0.010
Positive 132 (27.0) 55 (11.2) 152 (31.1) 150 (30.7)
Molecular Subtype Luminal 99 (25.4) 49 (12.6) 110 (28.3) 131 (33.7) 25.405 <0.001
HER2 Positive 34 (40.0) 10 (11.8) 24 (28.2) 17 (20.0)
Triple Negative 38 (36.2) 7 (6.7) 43 (41.0) 17 (16.2)
Ki67 labelling** Index Low 42 (23.0) 27 (14.8) 40 (21.9) 74 (40.4) 22.081 <0.001
High 83 (29.9) 30 (10.8) 101 (36.3) 64 (23.0)
p27 Low 114 (38.8) 33(11.2) 89 (30.3) 58 (19.7) 38.276 <0.001
High 40 (16.7) 33 (13.8) 77(32.1) 90 (37.5)
  1. *HER2 Status was assessed using American Society of Clinical Oncology/College of American Pathologists Guidelines Recommendations for HER2 Testing in Breast Cancer and Equivocal (2+) HER2+ cases were confirmed by FISH/CISH. ** Ki67 labelling index dichotomized at 14% according to St Galen consensus guidelines 2013
  2. Analysis within the whole unselected invasive breast cancer series with respect to receptor status, molecular subtype, Ki67 labeling index, and p27 demonstrated a statistically significant correlation across the four groups
\